The Evolution of Insulin Glargine and its Continuing Contribution to Diabetes Care

doi:10.1007/s40265-014-0226-4

	The Evolution of Insulin Glargine and its Continuing Contribution to Diabetes Care
	Hilgenfeld, Rolf 2,3,4; Seipke, Gerhard 1; Berchtold, Harald 1; Owens, David R.5
刊名	DRUGS
	2014-06
卷号	74 期号:8 页码:911-927
ISSN号	0012-6667
DOI	10.1007/s40265-014-0226-4
文献子类	Review
英文摘要	The epoch-making discovery of insulin heralded a new dawn in the management of diabetes. However, the earliest, unmodified soluble insulin preparations were limited by their short duration of action, necessitating multiple daily injections. Initial attempts to protract the duration of action of insulin involved the use of various additives, including vasoconstrictor substances, which met with limited success. The subsequent elucidation of the chemical and three-dimensional structure of insulin and its chemical synthesis and biosynthesis allowed modification of the insulin molecule itself, resulting in insulin analogs that are designed to mimic normal endogenous insulin secretion during both fasting and prandial conditions. Insulin glargine was the first once-daily, long-acting insulin analog to be introduced into clinical practice more than 10 years ago and is specifically designed to provide basal insulin requirements. It has a prolonged duration of action and no distinct insulin peak, making it suitable for once-daily administration and reducing the risk of nocturnal hypoglycemia that is seen with intermediate-acting insulins. Insulin glargine can be used in combination with prandial insulin preparations and non-insulin anti-diabetic agents according to individual requirements.
资助项目	Chinese Academy of Sciences through a Visiting Professorship for Senior International Scientists[2010T1S6] ; Sanofi[00000000]
WOS关键词	AMINO-ACID-SEQUENCE ; LONGACTING BASAL INSULIN ; NON-INFERIORITY TRIAL ; TO-TARGET TRIAL ; GROWTH-FACTOR-I ; NPH INSULIN ; PANCREATIC EXTRACTS ; OPEN-LABEL ; HOE 901 ; SUBCUTANEOUS INJECTION
WOS研究方向	Pharmacology & Pharmacy ; Toxicology
语种	英语
出版者	ADIS INT LTD
WOS记录号	WOS:000344616100006
内容类型	期刊论文
源URL	[http://119.78.100.183/handle/2S10ELR8/277036]
专题	中国科学院上海药物研究所
通讯作者	Hilgenfeld, Rolf
作者单位	1.Sanofi Aventis Deutschland GmbH, Frankfurt, Germany; 2.Univ Lubeck, Ctr Struct & Cell Biol Med, Inst Biochem, D-23538 Lubeck, Germany; 3.Univ Lubeck, Ctr Brain Behav & Metab, D-23538 Lubeck, Germany; 4.Shanghai Inst Mat Med, Shanghai, Peoples R China; 5.Swansea Univ, Coll Med, Inst Life Sci, Diabet Res Grp, Swansea, W Glam, Wales
推荐引用方式 GB/T 7714	Hilgenfeld, Rolf,Seipke, Gerhard,Berchtold, Harald,et al. The Evolution of Insulin Glargine and its Continuing Contribution to Diabetes Care[J]. DRUGS,2014,74(8):911-927.
APA	Hilgenfeld, Rolf,Seipke, Gerhard,Berchtold, Harald,&Owens, David R..(2014).The Evolution of Insulin Glargine and its Continuing Contribution to Diabetes Care.DRUGS,74(8),911-927.
MLA	Hilgenfeld, Rolf,et al."The Evolution of Insulin Glargine and its Continuing Contribution to Diabetes Care".DRUGS 74.8(2014):911-927.